• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Gain Therapeutics, Inc. - Common Stock (NQ:GANX)

    1.910 +0.020 (+1.06%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Apr 28, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 310,804
    Open 1.890
    Bid (Size) 1.860 (55)
    Ask (Size) 1.990 (2)
    Prev. Close 1.890
    Today's Range 1.840 - 1.960
    52wk Range 0.8900 - 3.190
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Gain Therapeutics Presents Additional Preclinical Data and Design of Phase 1b Clinical Study of GT-02287 at AD/PD 2025 and Provides Enrollment Update
    From Gain Therapeutics, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga

    Performance

    YTD
    -17.7%
    -17.7%
    1 Month
    N/A
    N/A
    3 Month
    -10.7%
    -10.7%
    6 Month
    -27.9%
    -27.9%
    1 Year
    -36.3%
    -36.3%

    More News

    Read More
    Gain Therapeutics Announces Poster Presentation at AD/PD 2025
    From Gain Therapeutics, Inc.
    Via GlobeNewswire
    Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2024 and Provides Corporate Update
    From Gain Therapeutics, Inc.
    Via GlobeNewswire
    Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson’s Disease
    Via Get News
    Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson's Disease
    Via ACCESS Newswire
    Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson’s Disease
    From Gain Therapeutics, Inc.
    Via GlobeNewswire
    Gain Therapeutics Announces Oral Presentation at AD/PD 2025
    From Gain Therapeutics, Inc.
    Via GlobeNewswire
    Gain Therapeutics CEO Gene Mack Issues Letter To Shareholders and Provides Operational Update
    From Gain Therapeutics, Inc.
    Via GlobeNewswire
    Gain Therapeutics To Participate in Upcoming Investor Conferences
    From Gain Therapeutics, Inc.
    Via GlobeNewswire
    Gain Therapeutics Announces Formation of Clinical Advisory Board to Support Continued Advancement of Lead Drug Candidate GT-02287
    From Gain Therapeutics, Inc.
    Via GlobeNewswire
    Gain Therapeutics Appoints Gene Mack as Chief Executive Officer and Director
    From Gain Therapeutics, Inc.
    Via GlobeNewswire
    Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson’s Disease
    From Gain Therapeutics, Inc.
    Via GlobeNewswire
    Gain Therapeutics To Present At Biotech Showcase 2025
    From Gain Therapeutics, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Friday's Pre-Market Session
    Via Benzinga
    Gain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate Update
    From Gain Therapeutics, Inc.
    Via GlobeNewswire
    Gain Therapeutics Presents Data at 36ᵗʰ EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Demonstrating Identification of Allosteric Inhibitors Targeting DDR2
    From Gain Therapeutics, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Tuesday's After-Market Session
    Via Benzinga
    Gain Therapeutics Announces Poster Presentation at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
    From Gain Therapeutics, Inc.
    Via GlobeNewswire
    Gain Therapeutics to Present at Michael J. Fox Foundation’s 16th Annual Parkinson’s Disease Therapeutics Conference
    From Gain Therapeutics, Inc.
    Via GlobeNewswire
    Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024
    From Gain Therapeutics, Inc.
    Via GlobeNewswire
    Gain Therapeutics to Participate at Upcoming Investor Conferences
    From Gain Therapeutics, Inc.
    Via GlobeNewswire
    Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson’s Disease and Movement Disorders Demonstrating Increase in GCase Activity in Healthy Volunteers
    From Gain Therapeutics, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    Gain Therapeutics To Host Virtual Webinar on Results From Phase 1 Study and Design of Upcoming Phase 1b Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease
    From Gain Therapeutics, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Gain Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Gain Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Gain Therapeutics, Inc. - Common Stock trade on?
    Gain Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Gain Therapeutics, Inc. - Common Stock?
    The ticker symbol for Gain Therapeutics, Inc. - Common Stock is GANX on the Nasdaq Stock Market
    What is the current price of Gain Therapeutics, Inc. - Common Stock?
    The current price of Gain Therapeutics, Inc. - Common Stock is 1.910
    When was Gain Therapeutics, Inc. - Common Stock last traded?
    The last trade of Gain Therapeutics, Inc. - Common Stock was at 04/28/25 04:00 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms Of Service.